Velox LB is a vascular closure device that leverages and improves on technology from velox CD™ for large bore (12-18 Fr) percutaneous procedures such as TAVR and EVAR. The implant is fabricated from a proprietary absorbable magnesium alloy that allows for the fast absorption and uncrompromised femoral perfusion. 

April 2017

Transluminal has completed the First-in-Man clinical study
with 100% Procedural Success.

Time to Hemostasis (TTH):  3.1 ± 3.1 min

and was 2.4 ± 2.4 min in patients with device success (9/10). 

Time to Ambulation (TTA):  Nine out of ten patients were allowed to get out of bed
at 2.0 ± 0.3 hr post procedure.

For investigational use only